Cordycepin Inhibits Growth and Metastasis Formation of MDA-MB-231 Xenografts in Nude Mice by Modulating the Hedgehog

Wenya Wu1,2, Xiaomin Li1,2, Meng Qi1,2

  • 1College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China.

Insights

Cordycepin effectively inhibits triple-negative breast cancer (TNBC) growth and metastasis in vivo by targeting the Hedgehog pathway. This study validates cordycepin

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cordycepin previously showed in vitro inhibition of MDA-MB-231 cell growth and metastasis via the Hedgehog pathway.
  • Validation of cordycepin's in vivo efficacy and mechanism against triple-negative breast cancer (TNBC) was lacking.

Purpose of the Study:

  • To confirm cordycepin's anti-TNBC effects in vivo.
  • To elucidate the mechanism of cordycepin's action in TNBC, focusing on the Hedgehog pathway.

Main Methods:

  • In vivo xenograft models using MDA-MB-231 cells in nude mice.
  • RNA sequencing, pathway enrichment, and protein network analysis.
  • Western blotting and immunohistochemistry to validate pathway inhibition.

Main Results:

  • Cordycepin significantly reduced xenograft volume and weight with no observed side effects.
  • Hedgehog pathway components (SHH, GLI2) were identified as key targets.
  • Hedgehog pathway activation correlates with poor survival in breast cancer patients.

Conclusions:

  • Cordycepin demonstrates in vivo efficacy against TNBC by inhibiting the Hedgehog pathway.
  • Targeting the Hedgehog pathway with cordycepin offers a potential therapeutic strategy for TNBC.
  • This study provides novel insights into cordycepin's mechanism for treating breast cancer.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K